Omeperazole Powder or Omeprazole Pellets 8.5%, 12.5%

• Customization: Available
• Function: Hormones and Regulation of Endocrine Function of Drug, Antibiotic and Antimicrobial Agents, Antiparasitic, Immune System Drugs, Specialist Drugs, Drug Detoxification, Diagnostic Agents, Nervous System Drugs, Blood System Agents, Enzymes and Other Biochemical, Visceral System Medication, Cardiovascular Agents, Urinary System Agents, Antidote
• Certification: GMP, Reach, FDA
• Model NO.: powder/pellets
• Grade Standard: Medicine Grade
• Type: Chemical Reagent
• State: Solid
• Volatile: Not Volatile
• Package: 25kg
• Transport Package: According to Customer Requirements
• Specification: Customized on demand
• Trademark: none
• Origin: China

Product Description

Omeprazole (omeprazole) is a kind of proton pump inhibitor used for the treatment of peptic ulcer and gastroesophageal reflux disease (GERD) and other diseases. The active form of sulfonamide is then irreversibly combined with the sulfhydryl group of the proton pump through a disulfide bond to generate a complex of sulfenamide and proton pump (H+-K+-ATPase), thereby inhibiting the enzyme activity and making the intracellular H+ cannot be transported into the gastric cavity, blocking the final step of gastric acid secretion, which can greatly reduce the amount of gastric acid in the gastric juice. Therefore, this product has a strong and lasting inhibitory effect on gastric acid secretion caused by various reasons (such as basal gastric acid secretion and gastric acid secretion caused by histamine, pentagastrin and stimulation of the vagus nerve, including blocking of H2 receptors. gastric acid secretion caused by dibutyl cyclic adenylate that cannot be inhibited by drugs). This has a certain relationship with the irreversibility of the inhibitory effect of this product on the proton pump, and the acid secretion can be restored only after the formation of a new proton pump. Omeprazole was developed by the Swedish AstraZeneca Pharmaceutical Company and was first marketed in Sweden under the trade name Losec in 1988. By 1992, it had been approved and used in 65 countries and regions, and it was listed as a best-selling drug in the world for three consecutive years from 1998 to 2000. No. 1 with sales of $5.2 billion in 2002.